Elizabeth Price

Elizabeth Price has investigated the potential anti-cancer effects of low-molecular-weight heparin beyond anticoagulation, studying whether LMWH inhibits cancer metastasis through blockade of selectin-mediated cancer cell adhesion, heparanase inhibition, and interference with growth factor signaling. Her analysis of clinical trial data has contributed to understanding whether anticoagulation duration affects cancer survival beyond VTE prevention. She has studied the CLOT trial data showing potential survival benefits of dalteparin in cancer subgroups. Her research explores the intersection of hemostasis and cancer biology.